VANCOUVER, British Columbia, January 9, 2025 (GLOBE NEWSWIRE) — Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company” or “Cannabix”) marijuana developer and Breathalyzer devices are pleased to announce that they have made significant updates to their Cannabix Marijuana Breathalyzer (“CMB”) technology for respond to suggestions. emerging regulatory requirements in preparation for commercialization. Cannabix engineers have integrated several new features into the company’s Breath Collection Unit (“BCU”) – a critical hardware tool used for portable collection of delta-9 THC in breath (images below ). These developments come as the need for marijuana breath detection intensifies in the United States and around the world.
Cannabix Breath Collection Unit (“BCU”) with Breath Cartridge Technology.
A recently published New York Times article, “As Marijuana Use Rises, Impact on Road Safety Remains a Blind Spot” (January 2025) highlights US federal research on traffic safety and cannabis use, as well as the lack of tools to detect cannabis-impaired driving (1). Additionally, the article discusses the limitations of existing testing methods for delta-9 THC and the increasing number of Americans using cannabis. The article refers to a survey conducted in 2019 by the AAA Foundation for Traffic Safety where approximately 14.8 million drivers (in the United States) reported getting behind the wheel within an hour of using marijuana, and 70% of Americans think it is unlikely that a driver will be arrested by the police for driving under the influence of marijuana (2). Cannabix’s marijuana breathalyzer technology focuses on detecting “recent use” of delta-9 THC, as opposed to widely used methods in urine, blood, and saliva (which can detect delta-9 THC several hours, days or even weeks after consumption) (3).
Rav Mlait, CEO of Cannabix, said: “Cannabix is at the forefront of marijuana-based breath testing technology, and we expect 2025 to mark significant milestones as the company matures its technology, partnerships and opportunities. commercial. In the United States, cannabis legalization has expanded to 39 states for medical use and 24 states for recreational use. This represents a major growth opportunity for Cannabix in the drug testing segment.
New Cannabix Breath Collection Unit (“BCU”) with Breath Cartridge technology.
Highlights:
- Cannabix provides updated images of its Breath Collection Unit (“BCU”) and Breathing cartridge technology with several new features to the Company’s marijuana breathalyzer technology to meet industry requirements and suggested emerging regulatory requirements.
- Major updates and improvements to the BCU include a smaller, lighter, more ergonomic design and a new removable, long-lasting, rechargeable Li-ion battery, allowing for easy battery replacement.
- The sample collection cartridge has been modified to collect a single or double sample, consistent with federally regulated programs that require simultaneous collection of A and B samples. Additionally, new ambient air collection via a second cartridge is now available.
- New “on-demand” periodic quality assurance check, new startup self-check feature and simplified user interface.
- Cannabix is rapidly advancing its marijuana breathalyzer technology, with key validation work underway in the United States.
References:
(1) https://www.nytimes.com/2025/01/01/us/marijuana-driving-impairment.html
(2) https://newsroom.aaa.com/2019/06/americans-dont-think-they’ll-get-arrested-for-driving-high/
(3) Olla P, Ishraque MT, Bartol S. 2020. Assessment of trends in breath and plasma tetrahydrocannabinol concentration after cannabis exposure in medical cannabis patients. Cannabis and cannabinoid resins; 99-104.
About Cannabix Technologies Inc.
Cannabix Technologies Inc. is a developer of marijuana and alcohol breath testing technologies for law enforcement, workplaces and laboratories. Cannabix is developing screening devices for delta-9 THC and alcohol. Delta-9 THC is the main psychoactive ingredient in cannabis. Breath testing for delta-9 THC would allow employers and law enforcement to identify recent marijuana use. Cannabix is the developer of its Breath Logix series of breath alcohol detection devices for employers and a range of other contexts.
We’re looking for Safe Harbor.
On behalf of the board of directors
“Rav Mlait”
CEO
Cannabix Technologies Inc.
For more information, contact the Company at info@cannabixtechnologies.com
Caution Regarding Forward-Looking Statements
This press release contains certain “forward-looking statements” within the meaning of such statements under applicable securities laws. Forward-looking statements are frequently characterized by words such as “anticipates”, “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates,” “may,” “will,” “potential,” “proposed,” “positioned,” and other similar words, or statements that certain events or conditions “may” or “will” occur. Forward-looking statements contained in this press release include, without limitation limit, statements relating to: the achievement of all or part of the objectives and objectives of the partnerships as described in this press release; final development of one or more commercial products or prototypes; company technologies; the commercialization of the Company’s products; the negotiation and possible conclusion of additional agreements with existing and new partners and the realization of future financings; There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information. Important factors that could cause actual results to differ materially from those expressed in the forward-looking information include (but are not limited to): adverse market conditions; risks related to the protection of proprietary technology; the Company’s ability to carry out future financing; the Company’s ability to develop and market its future product; risks relating to government regulation, managing and sustaining growth, the effect of adverse publicity, litigation, competition; that the partners may not complete all or part of the steps provided for in the planned strategic partnership agreements; that the CSE cannot approve the issuance of securities; that the development of breathalyzer technology by the Company will provide benefits to the Company; there can be no assurance that proposed new products will be constructed, pass beta testing or clinical trials; there can be no assurance that the Company will enter into partnerships to advance any of its business initiatives or technologies; there can be no assurance that any “patent pending” or “provisional patent” technologies licensed by or owned by the Company will receive patent status with regulatory authorities; the Company does not currently sell breathalyzers and there is no guarantee that it ever will; and other factors beyond the Company’s control. Actual results and future events could differ materially from those anticipated in this information. These subsequent written and oral forward-looking information, and all subsequent forward-looking information, are based on estimates and opinions of management as of the dates they are made and are expressly qualified in their entirety by this opinion. Except as required by law, the Company does not intend to update these forward-looking statements.
The CSE has not reviewed and accepts no responsibility for the adequacy or accuracy of this release.
